Phase I Dose Escalation Trial of Single Fraction Adjuvant Stereotactic Body Partial Breast irradiation (SB-PBI) For Early Stage Breast Cancer

Brief description of study

In this study, early-stage breast cancer patients will be receiving a single fraction (radiation dose) via FDA-approved Cyberknife technology. The main goal of this study is to identify the ideal single dose of level for treatment, and assess cosmesis (preservation and appearance of the breast).


Clinical Study Identifier: s18-01764
ClinicalTrials.gov Identifier: NCT02685332
Principal Investigator: Jonathan Haas.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.